4894.T
Cuorips Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 5,300.00
−2.39%Income statement
| Metric | TTM | 2026 | 2025 | 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | 356.0M | 212.0M | 175.0M | 23.0M |
| Cost of Revenue | 54.8M | 82.0M | 7.0M | 13.5M |
| Gross Profit | 30.5M | 130.4M | 168.3M | 9.6M |
| Operating Expenses | ||||
| R&D Expense | — | — | — | — |
| SG&A Expense | 227.0M | 1.2B | 758.5M | 598.1M |
| General & Admin Expense | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — |
| Other Expenses | — | — | — | — |
| Total Operating Expenses | 227.0M | 1.2B | 758.5M | 598.1M |
| Cost and Expenses | 1.2B | 1.3B | 765.0M | 611.0M |
| Operating Income (EBIT) | (797.0M) | (1.1B) | (590.0M) | (588.0M) |
| Non-Operating | ||||
| Interest Income | 2.7M | 13.4M | 4.1M | 45.0K |
| Interest Expense | — | — | — | — |
| Net Interest Income | — | — | — | — |
| Other Non-Op Income/Expense | (3.1M) | 52.7M | (51.8M) | (39.4M) |
| Non-Operating Income (excl Interest) | — | 39.3M | 3.1M | 1.4M |
| EBT (Pre-Tax Income) | (199.6M) | (1.0B) | (642.0M) | (630.0M) |
| Income Tax Expense | 1.2M | 3.8M | 3.3M | 2.2M |
| Bottom Line | ||||
| Net Income | (765.0M) | (1.0B) | (644.0M) | (632.0M) |
| Earnings from Cont. Ops | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — |
| Bottom Line Net Income | (765.0M) | (1.0B) | (644.0M) | (632.0M) |
| Per Share | ||||
| Basic EPS | (¥94) | (¥124) | (¥81) | (¥86) |
| Diluted EPS | (¥94) | (¥124) | — | — |
| Revenue Per Share | ¥43 | ¥26 | ¥22 | ¥3 |
| Shares | ||||
| Basic Shares Outstanding | 8.2M | 8.2M | 8.0M | 7.4M |
| Diluted Shares Outstanding | — | — | — | — |
| Profitability Metrics | ||||
| EBITDA | — | (996.5M) | (513.3M) | (517.9M) |
| D&A | — | 84.5M | 76.7M | 70.1M |
| EBIT | (797.0M) | (1.1B) | (590.0M) | (588.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026